Stephania delavayi Diels. inhibits breast carcinoma proliferation through the p38 MAPK/NF-κB/COX-2 pathway

Oncology Reports

Volumn 26, Issue 4, 2011, Pages 833-841

  Park, Dae Hun ^a   Xu, Hong De ^b   Shim, Jaegal ^c   Li, Yong Chun ^d   Lee, Jong Hwawa ^a   Cho, Soon Chang ^e   Han, Sang Seop ^f   Lee, Yun Lyul ^g   Lee, Min Jae ^d   Kwon, Sung Won ^h  

^a Korea Institute of Toxicology   (South Korea)

^b ZHENGZHOU UNIVERSITY   (China)

^c National Cancer Center   (South Korea)

^d Kangwon National University   (South Korea)

^e Youngdong University   (South Korea)

^f Hoseo University   (South Korea)

^g Hallym University   (South Korea)

^h CHA University   (South Korea)

Author keywords

Apoptosis; Breast carcinomas; COX 2; Nuclear factor B; Stephania delavayi Diels.

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; PLANT EXTRACT; STEPHANIA DELAVAYI EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; BREAST CARCINOMA; CELL PROLIFERATION; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEPHANIA; STEPHANIA DELAVAYI;

ANIMALS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLOOXYGENASE 2; FEMALE; FERNS; HUMANS; MICE; MICE, NUDE; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLANT EXTRACTS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960820275     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1364     Document Type: Article

References (42)

1. Cano E and Mahadevan LC: Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 20: 117-122, 1995.
2. Herlaar E and Brown Z: p38MAPK signaling cascades in inflammatory disease. Mol Med Today 5: 439-447, 1999. (Pubitemid 29455026)
3. Luo JL, Kamata H and Karin M: IKK/NF-kappaB signaling: balancing life and death, a new approach to cancer therapy. J Clin Invest 115: 2625-2632, 2005. (Pubitemid 41434385)
4. Sun XF and Zhang H: NFκB and NFκBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histophatol 22: 1387-1398, 2007.
5. Monks NR, Biswas DK and Pardee AB: Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-kappaB as a target. J Cell Biochem 92: 646-650, 2004. (Pubitemid 44264255)
6. St-Germain ME, Gagnon V, Parent S and Asselin E: Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway. Mol Cancer 3: 7, 2004.
7. Monks NR and Pardee AB: Targeting the NF-kappaB pathway in estrogen receptor negative MDA-MB-231 breast cancer cells using small inhibitory RNAs. J Cell Biochem 98: 221-233, 2006.
8. Jang BC, Sanchez T, Schaefers HJ, et al: Serum withdrawal-induced post-transcriptional stabilization of cyclooxygenase-2 mRNA in MDA-MB-231 mammary carcinoma cells requires the activity of the p38 stress-activated protein kinase. J Biol Chem 275: 39507-39515, 2000. (Pubitemid 32058977)
9. Karin M, Yamamoto Y and Wang QM: The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3: 17-26, 2004. (Pubitemid 38088695)
10. Orlowski RZ and Baldwin AS Jr: NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8: 385-389, 2002.
11. Guttridge DC, Albanese C, Reuther JY, et al: NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19: 5785-5799, 1999. (Pubitemid 29339933)
12. Dannenberg AJ, Altorki NK, Boyle J, et al: Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2: 544-551, 2001. (Pubitemid 33586867)
13. Thun MJ, Henley SJ and Patrono C: Non-steroidal anti-inflam-matory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266, 2002. (Pubitemid 34196319)
14. Park DH, Li YC, Shim J, et al: Biological safety and B cells activiation effects of Stephania delavayi Diels. Mol Cell Toxicol 5: 93-98, 2009.
15. Kikukawa Y, Okuno Y, Tatetsu H, et al: Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a biscoclaurine alkaloid. Int J Oncol 33: 807-814, 2008.
16. Meng LH, Zhang H, Hayward L, et al: Tetrandrine induces early G1 arrest in human colon carcinoma cells by down-regulating the activity and inducing the degradation of G1-S-specific cyclin-dependent kinases and by inducing p53 and p21Cip1. Cancer Res 64: 9086-9092, 2004. (Pubitemid 39665522)
17. Yasukawa K, Akasu M, Takeuchi M, et al: Bisbenzylisoquinoline alkaloids inhibit tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin. Oncology 50: 137-140, 1993. (Pubitemid 23098734)
18. DiPaola RS, Zhang H, Lambert GH, et al: Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 339: 785-791, 1998. (Pubitemid 28447451)
19. Halicka H, Ardelt B, Juan G, et al: Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC SPES. Int J Oncol 11: 437-448, 1997. (Pubitemid 27364273)
20. S Serrano MJ, Sanchez-Rovira P, Algarra I, et al: Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines. Jpn J Cancer Res 93: 559-566, 2002.
21. Merlin JL, Barberi-Heyob M and Bachman N: In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER2-expressing human breast cancer cell lines. Ann Oncol 13: 1743-748, 2002. (Pubitemid 35439454)
22. Tsatsanis C, Androulidaki A, Venihaki M, et al: Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 38: 1654-1661, 2006. (Pubitemid 43947653)
23. Sakai N, Wada T, Furuichi K, et al: p38MAPK phosphorylation and NF-κB activation in human crescentic glomerulonephritis. Nephrol Dial Transplant 17: 998-1004, 2002. (Pubitemid 34746201)
24. Alpert D, Schwenger P, Han J, et al: Cell stress and MKK6b-mediated p38MAP kinase activation inhibit tumor necrosis factor-induced IκB phosphorylation and NF-κB activation. J Biol Chem 274: 22176-22183, 1999.
25. Schwenger P, Bellosta P, Vietor I, et al: Sodium salicylate induces apoptosis via 38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci USA 94: 2869-2873, 1997. (Pubitemid 27157231)
26. Kwon KS and Chae HJ: Sodium salicylate inhibits expression of COX-2 through suppression of ERK and subsequent NF-κB activation in rat ventricular cardiomyocytes. Arch Pharm Res 26: 545-553, 2003.
27. Kumar AP, Bhaskaran S, Ganapathy M, et al: Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res 13: 2784-2794, 2007. (Pubitemid 46788048)
28. Ghosh R, Garcia GE, Crosby K, et al: Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. Neoplasia 9: 893-899, 2007. (Pubitemid 350086434)
29. Goebeler M, Gillitzer R, Kilian K, et al: Multiple signaling pathways regulate NF-κB-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells. Blood 97: 46-55, 2001.
30. van Hogerlinden M, Rozell BL and Ahrlund-Richter L, et al: Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res 59: 3299-3303, 1999.
31. Miyamoto S, Maki M, Schmitt MJ, et al: Tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha is a signal for its degradation but not dissociation from NF-kappaB. Proc Natl Acad Sci USA 91: 12740-12744, 1994.
32. Yang G, Yu F, Fu H, et al: Identification of the distinct promoters for the two transcripts of apoptosis related protein 3 and their transcriptional regulation by NFAT and NFkappaB. Mol Cell Biochem 302: 187-194, 2007. (Pubitemid 47202334)
33. Herrmann JL, Beham AW, Sarkiss M, et al: Bcl-2 suppresses apoptosis resulting from disruption of the NF-kappaB survival pathway. Exp Cell Res 237: 101-109, 1997 (Pubitemid 27528034)
34. Notarbartolo M, Poma P, Perri D, et al: Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-κB activation levels and in IAP gene expression. Cancer Lett 224: 53-65, 2005. (Pubitemid 40720367)
35. Wang CY, Mayo MW, Korneluk RG, et al: NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683, 1998.
36. Bian X, McAllister-Lucas LM, Shao F, et al: NF-kappaB activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem 276: 48921-48929, 2001.
37. Ryan KM, Ernst MK, Rice NR, et al: Role of NF-kappaB in p53-mediated programmed cell death. Nature 404: 892-897, 2000. (Pubitemid 30230343)
38. Ivanov VN and Ronai Z: Down-regulation of tumor necrosis factor alpha expression by activating transcription factor 2 increases UVC-induced apoptosis of late-stage melanoma cells. J Biol Chem 274: 14079-14089, 1999.
39. Schwabe RF and Brenner DA: Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol 283: G204-G211, 2002. (Pubitemid 34666179)
40. Park MK, Hwang SY, Kim JO, et al: NS398 inhibits the growth of Hep3B human hepatocellular carcinoma cells via caspase-independent apoptosis. Mol Cells 17: 45-50, 2004. (Pubitemid 39137043)
41. Zhong H, SuYang H, Erdjument-Bromage H, et al: The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP- independent mechanism. Cell 89: 413-424, 1997.
42. Chan FK, Hung LC, Suen BY, et al: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104-2110, 2002. (Pubitemid 36015122)